相关临床试验
27
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
18.5%
已完成
18
66.7%
尚未招募
2
7.4%
招募中
1
3.7%
暂无批准数据
- GlycoEra AG has appointed Petra Duda, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its precision immune degrader pipeline. - Dr. Duda brings over 20 years of experience in clinical development and regulatory strategy, with expertise in immune-mediated and rare diseases. - She will oversee advancement of GlycoEra's lead IgG4 degrader program GE8820 for autoimmune diseases including pemphigus, MuSK MG, and primary membranous nephropathy. - The appointment comes as GlycoEra advances its glyco-engineering platform designed to degrade disease-causing proteins without generalized immunosuppression.
- bluebird bio, a pioneer in gene therapies for severe genetic diseases, has appointed three new executives to strengthen its leadership team as the company focuses on commercial execution. - Brian Riley joins as President and Chief Technical Officer, bringing over 25 years of manufacturing and operations experience from companies including Beam Therapeutics and Catalent Pharma Solutions. - Dr. Joanne Lager has been named Chief Medical Officer, contributing more than 20 years of drug development expertise from roles at NiKang Therapeutics, iTeos Therapeutics, and Sanofi. - Adrian Chaisson joins as Chief of Staff with strategic and operational leadership experience in advancing novel medicines from discovery through commercialization.
- The global protein therapeutics market reached an estimated $400 billion in value, driven by increasing pharmaceutical company investment in advanced protein-based drug development strategies. - Nearly 20 protein-based drugs received regulatory approval in 2023 for treating various diseases including cancer and metabolic disorders, demonstrating accelerated development in this therapeutic area. - Monoclonal antibodies dominate the protein therapeutics sector with an estimated market value of $48.5 billion by 2011, representing the largest segment ahead of insulin therapies. - The protein therapeutics market is projected to grow at a compound annual growth rate of approximately 13% during 2012-2014, significantly outpacing overall pharmaceutical market growth.
• Novartis's experimental oral multiple sclerosis drug FTY720 (fingolimod) demonstrated significant reduction in disease relapses and progression over a two-year study period compared to placebo. • The lower 0.5mg dose showed comparable efficacy to higher doses with improved safety profile, leading Novartis to pursue regulatory approval for this dosage. • Novartis plans simultaneous FDA and EU submissions by end of 2009, with potential US market launch as early as 2010 pending expedited review.
